Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trichomonas vaginalis | set domain proteins, putative | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Brugia malayi | Pre-SET motif family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Onchocerca volvulus | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0286 | 0.9775 | 1 | |
Schistosoma mansoni | glutaminase | 0.0292 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.0344 | 0.0344 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0255 | 0.8615 | 0.8566 |
Brugia malayi | TAR-binding protein | 0.0255 | 0.8615 | 0.8615 |
Echinococcus granulosus | tar DNA binding protein | 0.0255 | 0.8615 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0255 | 0.8615 | 0.8566 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0255 | 0.8615 | 0.8615 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0027 | 0 | 0.5 |
Trichomonas vaginalis | glutaminase, putative | 0.0292 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0255 | 0.8615 | 0.8566 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0255 | 0.8615 | 0.8615 |
Schistosoma mansoni | tar DNA-binding protein | 0.0255 | 0.8615 | 0.8566 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0 | 0.5 |
Toxoplasma gondii | histone lysine methyltransferase SET/SUV39 | 0.0036 | 0.0344 | 1 |
Brugia malayi | Pre-SET motif family protein | 0.0036 | 0.0344 | 0.0344 |
Mycobacterium ulcerans | glutaminase | 0.0292 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0 | 0.5 |
Brugia malayi | glutaminase DH11.1 | 0.0292 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0255 | 0.8615 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0255 | 0.8615 | 0.8566 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.8465 | 0.8465 |
Brugia malayi | RNA binding protein | 0.0255 | 0.8615 | 0.8615 |
Echinococcus granulosus | histone lysine methyltransferase setb | 0.0036 | 0.0344 | 0.006 |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.8465 | 0.8465 |
Plasmodium vivax | SET domain protein, putative | 0.0036 | 0.0344 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0255 | 0.8615 | 0.8615 |
Loa Loa (eye worm) | glutaminase | 0.0292 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0255 | 0.8615 | 0.8615 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | = 5.0119 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of GCN5L2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504398] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.